News
CMXHF
77.89
NaN%
--
UBS Reaffirms Their Buy Rating on CSL (CMXHF)
TipRanks · 4d ago
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR) and CSL (OtherCMXHF)
TipRanks · 5d ago
CSL (CMXHF) Receives a Hold from Ord Minnett
TipRanks · 5d ago
Macquarie Keeps Their Hold Rating on CSL (CMXHF)
TipRanks · 5d ago
CSL Braces for EU Pullback of TAVNEOS After EMA Revocation Call
TipRanks · 6d ago
Lilly, Incyte, CSL among winners of EU drug recommendations this week
Seeking Alpha · 06/26 14:29
CHMP RECOMMENDS REVOKING MARKETING AUTHORISATION FOR TAVNEOS® (AVACOPAN) IN THE EUROPEAN UNION
Reuters · 06/26 13:00
ANALYSIS-US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Reuters · 06/25 10:00
US military requires flu vaccine for some after outbreak in Texas training center
Reuters · 06/24 18:26
Moderna: The Comeback Is Now In Full Swing
Seeking Alpha · 06/23 12:21
Ord Minnett Keeps Their Hold Rating on CSL (CMXHF)
TipRanks · 06/10 01:05
CSL Reports Lapse of 25,533 Conditional Rights, Limiting Potential Equity Dilution
TipRanks · 06/09 06:47
UBS Reaffirms Their Buy Rating on CSL (CMXHF)
TipRanks · 06/09 00:08
CSL Director Carolyn Hewson Increases Indirect Shareholding via On-Market Trade
TipRanks · 06/04 23:33
Ord Minnett Remains a Hold on CSL (CMXHF)
TipRanks · 06/03 06:46
BUZZ-Morningstar maintains fair value for CSL despite underperformance 
Reuters · 06/02 21:33
Analysts Are Neutral on These Healthcare Stocks: CSL (CMXHF), ONO Pharmaceutical Co (OPHLF)
TipRanks · 05/31 12:20
BUZZ-Australia's CSL falls on Jefferies downgrade to "hold"
Reuters · 05/29 05:36
CSL Director Restructures Shareholdings via Family Trust
TipRanks · 05/27 22:51
CSL (CMXHF) Receives a Buy from Morgan Stanley
TipRanks · 05/26 04:55
More
Webull provides a variety of real-time CMXHF stock news. You can receive the latest news about CSL through multiple platforms. This information may help you make smarter investment decisions.
About CMXHF
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.